vTv Therapeutics to Participate in the 38th Annual ROTH Conference
Rhea-AI Summary
vTv Therapeutics (Nasdaq: VTVT) said its management team will participate in a fireside chat and hold 1x1 investor meetings at the 38th Annual ROTH Conference in Dana Point, CA, March 22-24, 2026.
The fireside chat is scheduled for March 23, 2026 at 10:00 AM PDT and will be webcast live with a replay available on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – VTVT
In the Mar 16 session, VTVT gained 14.57%, reflecting a significant positive market reaction. Argus tracked a peak move of +11.2% during that session. Argus tracked a trough of -2.0% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Earnings and update | Positive | +0.2% | Q4 and 2025 results with cash position and CATT1 enrollment timing. |
| Feb 13 | Investor conferences | Neutral | -7.2% | Planned participation in two investor conferences with webcast availability. |
| Feb 02 | License amendment | Positive | +8.2% | Expanded global license for HPP737 with upfront, milestone, and royalty economics. |
| Dec 18 | Phase 2 protocol | Positive | +3.7% | Submission of 12‑month, 300‑patient Phase 2 study protocol for cadisegliatin in T2D. |
| Nov 06 | Earnings and financing | Positive | +2.2% | Q3 results, $80M private placement, CATT1 progress, and long-dated patent allowance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Stock has typically reacted positively to clinical, licensing, and financing updates, while neutral conference announcements have sometimes seen negative price follow-through.
Over the last several months, vTv issued multiple updates tied to cadisegliatin and its broader pipeline. A November 10-Q and earnings release highlighted strengthened liquidity and CATT1 trial progress, followed by December’s Phase 2 protocol submission for cadisegliatin in type 2 diabetes. A February amendment with Newsoara added global rights to HPP737 and an upfront payment, which coincided with a positive share reaction. By contrast, a February investor-conference announcement was followed by a sharp one-day decline, underscoring that not all outreach events have been rewarded.
Key Terms
type 1 diabetes medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in a fireside chat and conduct 1x1 investor meetings at the 38th Annual ROTH Conference, which is being held March 22-24, 2026, in Dana Point, CA.
| 38th Annual ROTH Conference: | |
| Format: | Fireside chat and 1x1 investor meetings |
| Date: | Monday, March 23, 2026 |
| Time: | 10:00 AM PDT |
| Webcast Link | |
A live webcast of the fireside chat will be available on the Media & Events section of the Company’s website at vtvtherapeutics.com. A replay of the webcast will be available following the event.
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
